ClinicalTrials.gg
CompletedNCT05116085Updated Feb 13, 2026Results posted

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

A Phase 2 interventional study of Tislelizumab in Colorectal Cancer, sponsored by BeiGene. Completed at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing tislelizumab in Colorectal Neoplasms — 15 open to participants now, 19 under way, 1 of them phase 3. tislelizumab · Colorectal Neoplasms.

Enrollment
12th of 27
33 · median 33
Started
2022
with 3 others
Phase 2
20 of 27
10 open now
Registered
4th of 27
by date
Lead sponsor
2 of 27
BeiGene

Among the 27 studies testing tislelizumab in Colorectal Neoplasms, this one is the 12th largest by enrollment, is one of 4 that started in 2022, is one of 20 in phase 2, and was the 4th registered.

Colorectal Neoplasms

6,545 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 27 studies testing tislelizumab in Colorectal Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing tislelizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study was to help meet the medical needs of people in China with certain types of solid tumors that have specific genetic changes called microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR). The study looked at how well the drug tislelizumab works and how safe it is when given before surgery (neoadjuvant treatment) for these types of tumors.

Read the detailed description

This study enrolled participants with Stage II or III resectable colorectal cancer (CRC). Participants with unknown microsatellite instability (MSI) or mismatch repair (MMR) status provided blood and tumor tissue samples during a prescreening period (within 56 days before the first dose) for central laboratory confirmation of MSI status. Participants with known MSI-high (MSI-H) or deficient MMR (dMMR) status by local laboratory also underwent central confirmation when tumor samples were available. Eligible participants received tislelizumab 200 mg by intravenous infusion once every 3 weeks for 3 cycles as neoadjuvant therapy. After completion of neoadjuvant treatment, participants underwent complete surgical removal (R0 resection) of their tumor, and surgical specimens were assessed for pathological response, including major pathological response (MPR) and pathological complete response (pCR). Post-surgery, participants continued adjuvant therapy and follow-up as determined by their investigator.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants had an (ECOG) Performance Status score of 0 or 1.
  • Participants had a pathologically (histologically) confirmed diagnosis of potentially resectable Stage II or Stage III colon or rectal cancer (CRC) with microsatellite instability-high (MSI-H) status confirmed by a sponsor-designated central laboratory, or known MSI-H status confirmed by a local laboratory. Participants were required to be eligible for complete surgical removal of the tumor (R0 resection) with curative intent.
  • Participants had evaluable or as assessed by the investigator according to the (RECIST), version 1.1.
  • Participants had adequate blood counts and organ function, as defined by protocol-specified laboratory test results obtained within 7 days before the first dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Participants had received any prior treatment for their current colorectal cancer, including chemotherapy, radiotherapy, or immunotherapy.
  • Participants had any condition requiring systemic treatment with at doses greater than 10 milligrams (mg) of prednisone per day, or other medications within 14 days before the first dose.
  • Participants had active diseases or a history of autoimmune diseases that could potentially relapse.

Note: Additional protocol-defined inclusion and exclusion criteria may have applied.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Tislelizumab

    Participants received tislelizumab 200 milligrams (mg) through an intravenous (IV) infusion once every 3 weeks for 3 treatment cycles before surgery (neoadjuvant therapy). After completing these 3 cycles, participants had their tumor surgically removed within 10 weeks of the first dose.

    Drug: Tislelizumab

Interventions

  • 200 milligrams (mg) administered through an intravenous (IV) infusion once every 3 weeks for 3 treatment cycles

    Also known as: BGB-A317, TEVIMBRA®

06

What researchers measure

Primary outcomes

  1. Major Pathological Response (MPR) Rate

    MPR rate is defined as the percentage of participants whose resected primary tumor shows 10% or less remaining viable cancer cells after completing neoadjuvant therapy.

    Time frame: Approximately 10 weeks after first dose of study treatment

Secondary outcomes

  1. Pathological Complete Response (pCR) Rate

    Defined as the percentage of participants with a complete absence of residual tumor (no remaining cancer cells) in the surgically resected primary tumor and in all resected lymph nodes after completing neoadjuvant therapy.

    Time frame: Approximately 10 weeks after first dose of study treatment

  2. Event Free Survival (EFS)

    Defined as the time from the first dose of study treatment until the first occurrence of any of the following events: * Disease progression that prevents complete surgical remover of the tumor * Local or distant recurrence after surgery * Death from any cause The median and other quartiles of EFS were estimated using the Kaplan-Meier Method.

    Time frame: From first dose to final analysis data cutoff (03JAN2025), disease progression, initiation of a new anticancer therapy, or death; whichever came first. Median follow-up was 21.7 months.

  3. 2-Year and 3-Year Event Free Survival (EFS)

    The 2-year and 3-year EFS rates are defined as the percentage of participants without any EFS events at 24 months and 36 months after the first dose. EFS rates were estimated by the Kaplan-Meier method with 95% CI estimated using Greenwood's formula.

    Time frame: 24 months and 36 months after first dose

  4. Number of Participants Experiencing Adverse Events

    The incidence of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and immune-mediated adverse events (imAEs), was assessed for all participants who received at least one dose of study treatment. SAEs were defined as events that resulted in death, were life-threatening, required or prolonged hospitalization, caused significant disability, or were considered important medical events. imAEs were defined as adverse events consistent with immune-related mechanisms, such as autoimmune-like toxicities requiring clinical evaluation or immunosuppressive management.

    Time frame: From the first dose until 30 days (or 90 days for imAEs) after the last dose of tislelizumab, death, or start of new anticancer therapy, whichever occurred first (up to 03JAN2025). Maximum treatment duration was 2.3 months.

07

Results

Posted Feb 13, 2026

Participant flow

Participants were enrolled in multiple study centers in China.

Participant flow — Overall Study
MilestoneTislelizumab
Started33
Received surgery29
Completed0
Not completed33
Withdrew: Study completed by sponsor30
Withdrew: Withdrawal by subject2
Withdrew: Death1

Outcome measures

PrimaryMajor Pathological Response (MPR) Rate

MPR rate is defined as the percentage of participants whose resected primary tumor shows 10% or less remaining viable cancer cells after completing neoadjuvant therapy.

Time frame:
Approximately 10 weeks after first dose of study treatment
Reported as:
Number · Percentage of Participants
Major Pathological Response (MPR) Rate
Percentage of ParticipantsTislelizumab
Major Pathological Response (MPR) Rate89.7 (72.6 to 97.8)
SecondaryPathological Complete Response (pCR) Rate

Defined as the percentage of participants with a complete absence of residual tumor (no remaining cancer cells) in the surgically resected primary tumor and in all resected lymph nodes after completing neoadjuvant therapy.

Time frame:
Approximately 10 weeks after first dose of study treatment
Reported as:
Number · Percentage of Participants
Pathological Complete Response (pCR) Rate
Percentage of ParticipantsTislelizumab
Pathological Complete Response (pCR) Rate62.1 (42.3 to 79.3)
SecondaryEvent Free Survival (EFS)

Defined as the time from the first dose of study treatment until the first occurrence of any of the following events: * Disease progression that prevents complete surgical remover of the tumor * Local or distant recurrence after surgery * Death from any cause The median and other quartiles of EFS were estimated using the Kaplan-Meier Method.

Time frame:
From first dose to final analysis data cutoff (03JAN2025), disease progression, initiation of a new anticancer therapy, or death; whichever came first. Median follow-up was 21.7 months.
Reported as:
Median · Months
Event Free Survival (EFS)
MonthsTislelizumab
Event Free Survival (EFS)NA (NA to NA)
Secondary2-Year and 3-Year Event Free Survival (EFS)

The 2-year and 3-year EFS rates are defined as the percentage of participants without any EFS events at 24 months and 36 months after the first dose. EFS rates were estimated by the Kaplan-Meier method with 95% CI estimated using Greenwood's formula.

Time frame:
24 months and 36 months after first dose
Reported as:
Number · Percentage of Participants
2-Year and 3-Year Event Free Survival (EFS)
Percentage of ParticipantsTislelizumab
24 Months (2-Year)93.9 (77.9 to 98.4)
SecondaryNumber of Participants Experiencing Adverse Events

The incidence of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and immune-mediated adverse events (imAEs), was assessed for all participants who received at least one dose of study treatment. SAEs were defined as events that resulted in death, were life-threatening, required or prolonged hospitalization, caused significant disability, or were considered important medical events. imAEs were defined as adverse events consistent with immune-related mechanisms, such as autoimmune-like toxicities requiring clinical evaluation or immunosuppressive management.

Time frame:
From the first dose until 30 days (or 90 days for imAEs) after the last dose of tislelizumab, death, or start of new anticancer therapy, whichever occurred first (up to 03JAN2025). Maximum treatment duration was 2.3 months.
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events
ParticipantsTislelizumab
TEAEs33
Serious AEs4
imAEs10

Adverse events

Collected over All-cause mortality is reported from enrollment through to the end of the study, maximum duration was 35 months. Adverse events are reported from the first dose until 30 days (or 90 days for imAEs) after the last dose of tislelizumab, death, or start of new anticancer therapy, whichever occurred first; Maximum treatment duration was 2.3 months.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tislelizumab1/33 (3%)4/33 (12.1%)31/33 (93.9%)
Most frequent serious events
Most frequent serious events
EventTislelizumab
Cardiac arrestCardiac disorders1/33
MyocarditisCardiac disorders1/33
InflammationGeneral disorders1/33
Skin infectionInfections and infestations1/33
Most frequent other events
Showing 10 of 83
Most frequent other events
EventTislelizumab
AnaemiaBlood and lymphatic system disorders18/33
HypoalbuminaemiaMetabolism and nutrition disorders11/33
Wound complicationInjury, poisoning and procedural complications9/33
Weight decreasedInvestigations6/33
NauseaGastrointestinal disorders5/33
FatigueGeneral disorders5/33
C-reactive protein increasedInvestigations5/33
HyperglycaemiaMetabolism and nutrition disorders5/33
Sinus bradycardiaCardiac disorders4/33
HyperthyroidismEndocrine disorders4/33

Baseline characteristics

The Safety Analysis Set included all enrolled participants who received ≥ 1 dose of study drug

Age, Continuous
Age, Continuous(years)Tislelizumab
Mean51.9 ± 16.30
Sex: Female, Male
Sex: Female, Male(Participants)Tislelizumab
Female19
Male14
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tislelizumab
Chinese33
Region of Enrollment
Region of Enrollment(participants)Tislelizumab
China33
The Eastern Cooperative Oncology Group (ECOG) Performance Status
The Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Tislelizumab
0 (fully Active)27
1(Restrictive but Ambulatory)6
08

Study locations

8 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233004, China
  • Sun Yat Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • The Affiliated Hospital of Qingdao University Branch South
    Qingdao, Shandong 266000, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Sep 2023, 20 months.

Results were first posted in Feb 2026, 2 years 4 months after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 20 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2021
First posted
Nov 10, 2021
StartActual
Jan 26, 2022
Primary completionActual
Sep 26, 2023
CompletionActual
Jan 3, 2025
Results first posted
Feb 13, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05116085
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Nov 10, 2021
Start date
Jan 26, 2022
Primary completion
Sep 26, 2023
Completion
Jan 3, 2025
Results posted
Feb 13, 2026
Last update
Feb 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion